Anti-programmed cell death 1 antibody reduces CD4+PD-1 + T cells and relieves the lupus-like nephritis of NZB/W F1 Mice

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2337-2347

  Kasagi, Shimpei ^a   Kawano, Seiji ^a   Okazaki, Taku ^b   Honjo, Tasuku ^d   Morinobu, Akio ^a   Hatachi, Saori ^c   Shimatani, Kenichiro ^d   Tanaka, Yoshimasa ^d   Minato, Nagahiro ^d   Kumagai, Shunichi ^a  

^a KOBE UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c Kitano Hospital   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 21; IONOMYCIN; MONOCLONAL ANTIBODY; PROGRAMMED CELL DEATH 1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; B7 ANTIGEN; DIFFERENTIATION ANTIGEN; MEMBRANE PROTEIN; PD 1 ANTIGEN, MOUSE; PD-1 ANTIGEN, MOUSE; PDCD1LG1 PROTEIN, MOUSE; PDCD1LG2 PROTEIN, MOUSE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL INFILTRATION; CELL SECRETION; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG MECHANISM; EXPERIMENTAL MOUSE; FEMALE; INFLAMMATORY CELL; KIDNEY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MORTALITY; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN CELL; ANIMAL; BLOOD; CELL PROLIFERATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; NEPHRITIS; PATHOLOGY; SPLEEN; SURVIVAL RATE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; INTERFERON-GAMMA; KIDNEY; MALE; MEMBRANE GLYCOPROTEINS; MICE; NEPHRITIS; PEPTIDES; SPLEEN; SURVIVAL RATE;

EID: 77951887482     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901652     Document Type: Article

References (49)

1. Datta, S. K., A. Kaliyaperumal, and A. Desai-Mehta. 1997. T cells of lupus and molecular targets for immunotherapy. J. Clin. Immunol. 17: 11-20.
2. Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths, and F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148: 1198-1215.
3. Lin, L. C., Y. C. Chen, C. C. Chou, K. H. Hsieh, and B. L. Chiang. 1995. Dysregulation of T helper cell cytokines in autoimmune prone NZB x NZW F1 mice. Scand. J. Immunol. 42: 466-472.
4. Laskin, C. A., J. D. Taurog, P. A. Smathers, and A. D. Steinberg. 1981. Studies of defective tolerance in murine lupus. J. Immunol. 127: 1743-1747.
5. Mudd, P. A., B. N. Teague, and A. D. Farris. 2006. Regulatory T cells and systemic lupus erythematosus. Scand. J. Immunol. 64: 211-218.
6. Parry, R. V., J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553.
7. Sharpe, A. H., E. J. Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8: 239-245.
8. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11: 3887-3895.
9. Nishimura, H., N. Minato, T. Nakano, and T. Honjo. 1998. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10: 1563-1572.
10. Liang, S. C., Y. E. Latchman, J. E. Buhlmann, M. F. Tomczak, B. H. Horwitz, G. J. Freeman, and A. H. Sharpe. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33: 2706-2716.
11. Okazaki, T., Y. Iwai, and T. Honjo. 2002. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 14: 779-782.
12. Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151. (Pubitemid 29428807)
13. Nishimura, H., T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, A. Mizoguchi, H. Hiai, N. Minato, and T. Honjo. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319-322. (Pubitemid 32096320)
14. Okazaki, T., and T. Honjo. 2005. Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. Trends Mol. Med. 11: 322-326.
15. Ferreiros-Vidal, I., J. J. Gomez-Reino, F. Barros, A. Carracedo, P. Carreira, F. Gonzalez-Escribano, M. Liz, J. Martin, J. Ordi, J. L. Vicario, and A. Gonzalez. 2004. Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. Arthritis Rheum. 50: 2590-2597. (Pubitemid 39062720)
16. Bertsias, G. K., M. Nakou, C. Choulaki, A. Raptopoulou, E. Papadimitraki, G. Goulielmos, H. Kritikos, P. Sidiropoulos, M. Tzardi, D. Kardassis, et al. 2009. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum. 60: 207-218.
17. Hatachi, S., Y. Iwai, S. Kawano, S. Morinobu, M. Kobayashi, M. Koshiba, R. Saura, M. Kurosaka, T. Honjo, and S. Kumagai. 2003. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol. 30: 1410-1419. (Pubitemid 36835433)
18. Bolstad, A. I., H. G. Eiken, B. Rosenlund, M. E. Alarcón-Riquelme, and R. Jonsson. 2003. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum. 48: 174-185.
19. Kobayashi, M., S. Kawano, S. Hatachi, C. Kurimoto, T. Okazaki, Y. Iwai, T. Honjo, Y. Tanaka, N. Minato, T. Komori, et al. 2005. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome. J. Rheumatol. 32: 2156-2163. (Pubitemid 41587860)
20. Oikawa, T., H. Takahashi, T. Ishikawa, A. Hokari, N. Otsuki, M. Azuma, M. Zeniya, and H. Tajiri. 2007. Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol. Int. 57: 485-492.
21. Agata, Y., A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8: 765-772.
22. Ishida, M., Y. Iwai, Y. Tanaka, T. Okazaki, G. J. Freeman, N. Minato, and T. Honjo. 2002. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84: 57-62.
23. Heijnen, I. A., M. J. Glennie, and J. G. van de Winkel. 1997. Lysis of murine B lymphoma cells by transgenic phagocytes via a human FcγRI x murine MHC class II bispecific antibody. Cancer Immunol. Immunother. 45: 166-170.
24. Nozaki, Y., T. Yamagata, B. S. Yoo, M. Sugiyama, S. Ikoma, K. Kinoshita, M. Funauchi, and A. Kanamaru. 2005. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice. Clin. Exp. Immunol. 139: 74-83.
25. Salama, A. D., T. Chitnis, J. Imitola, M. J. Ansari, H. Akiba, F. Tushima, M. Azuma, H. Yagita, M. H. Sayegh, and S. J. Khoury. 2003. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198: 71-78.
26. Ansari, M. J., A. D. Salama, T. Chitnis, R. N. Smith, H. Yagita, H. Akiba, T. Yamazaki, M. Azuma, H. Iwai, S. J. Khoury, et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198: 63-69.
27. Jacob, C. O., P. H. van der Meide, and H. O. McDevitt. 1987. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J. Exp. Med. 166: 798-803.
28. Sato, M. N., P. Minoprio, S. Avrameas, and T. Ternynck. 1995. Defects in the regulation of anti-DNA antibody production in aged lupus-prone (NZB x NZW) F1 mice: analysis of T-cell lymphokine synthesis. Immunology 85: 26-32.
29. Gajewski, T. F., S. R. Schell, G. Nau, and F. W. Fitch. 1989. Regulation of T-cell activation: differences among T-cell subsets. Immunol. Rev. 111: 79-110.
30. La Cava, A., F. M. Ebling, and B. H. Hahn. 2004. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J. Immunol. 173: 3542-3548.
31. Enghard, P., D. Langnickel, and G. Riemekasten. 2006. T cell cytokine imbalance towards production of IFN-γ and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis. Scand. J. Rheumatol. 35: 209-216.
32. Schwarz, M., M. Wahl, K. Resch, and H. H. Radeke. 2002. IFNγ induces functional chemokine receptor expression in human mesangial cells. Clin. Exp. Immunol. 128: 285-294.
33. Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203: 883-895.
34. Schoop, R., P. Wahl, M. Le Hir, U. Heemann, M. Wang, and R. P. Wüthrich. 2004. Suppressed T-cell activation by IFN-γ-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol. Dial. Transplant. 19: 2713-2720.
35. Mazanet, M. M., and C. C. Hughes. 2002. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169: 3581-3588.
36. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
37. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
38. + type 1 T regulatory subset through IFN-γ-secreting Th1 cells. J. Immunol. 177: 3606-3614.
39. Ye, Y. L., J. L. Suen, Y. Y. Chen, and B. L. Chiang. 1998. Phenotypic and functional analysis of activated B cells of autoimmune NZB x NZW F1 mice. Scand. J. Immunol. 47: 122-126.
40. Hahn, B. H., F. Ebling, R. R. Singh, R. P. Singh, G. Karpouzas, and A. La Cava. 2005. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann. N. Y. Acad. Sci. 1051: 433-441.
41. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179: 305-310.
42. Cross, J. T., and H. P. Benton. 1999. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm. Res. 48: 255-261.
43. Avery, D. T., V. L. Bryant, C. S. Ma, R. de Waal Malefyt, and S. G. Tangye. 2008. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J. Immunol. 181: 1767-1779.
44. Wang, X. F., Y. J. Chen, Q. Wang, Y. Ge, Q. Dai, K. F. Yang, Y. H. Fang-Xie, Y. M. Zhou, Y. X. Hu, Mao, and X. G. Zhang. 2007. Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells. Tissue Antigens 69: 145-153. (Pubitemid 46174869)
45. Perrin, P. J., J. H. Maldonado, T. A. Davis, C. H. June, and M. K. Racke. 1996. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157: 1333-1336.
46. Butte, M. J., M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
47. Nakajima, A., M. Azuma, S. Kodera, S. Nuriya, A. Terashi, M. Abe, S. Hirose, T. Shirai, H. Yagita, and K. Okumura. 1995. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur. J. Immunol. 25: 3060-3069.
48. Hall, A. M., F. J. Ward, C. R. Shen, C. Rowe, L. Bowie, A. Devine, S. J. Urbaniak, C. J. Elson, and R. N. Barker. 2007. Deletion of the dominant autoantigen in NZB mice with autoimmune hemolytic anemia: effects on autoantibody and T-helper responses. Blood 110: 4511-4517.
49. Shen, C. R., G. Mazza, F. E. Perry, J. T. Beech, S. J. Thompson, A. Corato, S. Newton, R. N. Barker, and C. J. Elson. 1996. T-helper 1 dominated responses to erythrocyte Band 3 in NZB mice. Immunology 89: 195-199.